Comparing whole body 18f-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 6, 2002, Pages 325-328

  Yang, S ^a   Liang, J ^a   Lin, F ^a,b   Kao, C ^a   Lin, C ^a   Lee, C ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

18F 2 Deoxyglucose; Bone metastases; Bone scan; Breast cancer; Positron emission tomography; Technetium 99m methylene diphosphate

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOGRAPHY; TUMOR BIOPSY;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TECHNETIUM TC 99M MEDRONATE;

EID: 0036258054     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0342-5     Document Type: Article

References (16)

1. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
2. The clinical course of bone metastases from breast cancer
3. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesion
4. Technetium-99m MDP scintigraphy: An insensitive tool for the detection of bone marrow metastases
5. PET bone imaging
6. Bone scanning in metastatic disease
7. (18F)Fluorodeoxy glucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer
8. 18-F-Fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
9. Skeletal scanning in neoplastic disease
10. Skeletal metastases
11. Advanced breast cancer: Use of resources and cost implications
12. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
13. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection
14. False negative bone scans in disseminated metastatic disease
15. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
16. On the metabolism of tumors in the body